Ascentage Pharma Group International (HKG:6855)
Hong Kong
· Delayed Price · Currency is HKD | Market Cap | 23.39B |
| Revenue (ttm) | 428.02M |
| Net Income (ttm) | -1.27B |
| Shares Out | 368.05M |
| EPS (ttm) | -3.88 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,991,400 |
| Average Volume | 1,545,815 |
| Open | 62.85 |
| Previous Close | 60.85 |
| Day's Range | 61.15 - 65.00 |
| 52-Week Range | 31.35 - 95.35 |
| Beta | 1.11 |
| RSI | 47.57 |
| Earnings Date | Nov 19, 2025 |
About HKG:6855
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company’s primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid... [Read more]
Financial Performance
In 2024, HKG:6855's revenue was 980.65 million, an increase of 341.77% compared to the previous year's 221.98 million. Losses were -405.43 million, -56.20% less than in 2023.
Financial numbers in CNY Financial StatementsNews
Ascentage Gets Regulatory Clearance In The US And Europe To Conduct POLARIS-1 Trial
(RTTNews) - Suzhou, China-based Ascentage Pharma Group International (AAPG, 6855.HK) announced that the FDA and the European Medicines Agency have given clearance to conduct a global registrational Ph...
Ascentage Pharma To Launch Global Phase III Study Of Olverembatinib In Ph+ ALL
(RTTNews) - Ascentage Pharma Group International (AAPG, 6855.HK) announced that it received clearance from both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to lau...
This Hasbro Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag...
Ascentage Pharma Group (AAPG): Piper Sandler Initiates Coverage with Overweight Rating | AAPG ...
Ascentage Pharma Group (AAPG): Piper Sandler Initiates Coverage with Overweight Rating | AAPG Stock News
Ascentage Pharma Group International (AAPG) Presents At Citi's Biopharma Back To School Conference Transcript
Ascentage Pharma Group International GAAP EPS of -$0.24, revenue of $32.6M
Ascentage Pharma Group International (AAPG) Advances in Global Phase III Study for Higher-Risk ...
Ascentage Pharma Group International (AAPG) Advances in Global Phase III Study for Higher-Risk MDS Treatment | AAPG stock news
Ascentage Pharma Group International Announces Key Executive Appointments | AAPG stock news
Ascentage Pharma Group International Announces Key Executive Appointments | AAPG stock news
Chinese Biotech Ascentage Pharma's Valuation Driven By Late-Stage De-Risked Assets: JPMorgan
JPMorgan initiated coverage on Ascentage Pharma Group (NASDAQ: AAPG), a commercial-stage Chinese biotech company focusing on cancer treatment . In January, Ascentage Pharma’s American depositary shar...
Earnings Scheduled For March 27, 2025
Companies Reporting Before The Bell • Tsakos Energy Navigation (NYSE: TEN) is projected to report quarterly earnings at $0.40 per share on revenue of $154.43 million. • Worksport (NASDAQ: WKSP) is p...
Ascentage Pharma Group International (AAPG) Showcases Innovative Cancer Therapies at AACR 2025
Ascentage Pharma Group International (AAPG) Showcases Innovative Cancer Therapies at AACR 2025
Takeda-backed Ascentage Pharma aims to raise $126 mln in US IPO
Ascentage Pharma said on Thursday it aims to raise $126.4 million in an initial public offering in the United States, becoming the first sizeable Chinese firm to seek a listing in the U.S. this year.
Ascentage Pharma Announces Pricing of U.S. Initial Public Offering
ROCKVILLE, Md. and SUZHOU, China, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (Nasdaq: AAPG) (HKEX: 6855) announced today the pricing of its U.S. initial public offering of 7,325,000 American d...
Takeda-backed Ascentage Pharma targets $1.75 billion valuation in US IPO
China-based Ascentage Pharma said on Tuesday it was targeting a valuation of $1.75 billion in its initial public offering in the United States.
Ascentage Pharma to Present at 43rd Annual J.P. Morgan Healthcare Conference
ROCKVILLE, Md. and SUZHOU, China , Dec. 26, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to add...
Live from ASH 2024 | Oral Report Features Encouraging Data of Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax in R/R MM, Including a Median PFS Over 9 Months
ROCKVILLE, Md. and SUZHOU, China , Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to add...
Live from ASH 2024 | Ascentage Pharma Releases Updated Data of Bcl-2 Inhibitor Lisaftoclax in MDS that Demonstrates Potential Clinical Benefits and Favorable Safety
ROCKVILLE, Md. and SUZHOU, China , Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to add...
Live from ASH 2024 | Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax in Combinations Demonstrates Potential Clinical Benefit in Patients with Prior Exposure to Venetoclax
ROCKVILLE, Md. and SUZHOU, China , Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to add...
Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors
ROCKVILLE, Md. and SUZHOU, China , Nov. 24, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to addr...
Ascentage Pharma Announces a New Drug Application for Its Novel Bcl-2 Inhibitor Lisaftoclax Accepted and Recommended Priority Review Designation by CDE of China NMPA
ROCKVILLE, Md. and SUZHOU, China , Nov. 17, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to addr...
ASH 2024 | Results From Three Clinical Studies of Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax Selected for Presentations, Including an Oral Report
ROCKVILLE, Md. and SUZHOU, China , Nov. 6, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to addr...
Live from ESMO 2024 | Ascentage Pharma Releases Latest Data Showing Sustained Clinical Efficacy of Olverembatinib in SDH-Deficient GIST during a Mini Oral Presentation
ROCKVILLE, Md. and SUZHOU, China , Sept.
ESMO 2024 | Ascentage Pharma to Present Updated Data of Olverembatinib in Patients with SDH-Deficient GIST during a Mini Oral Presentation at the 2024 ESMO Congress
ROCKVILLE, Md. and SUZHOU, China , Sept.
Ascentage Pharma Announces 2024 Interim Results
ROCKVILLE, Md. and SUZHOU, China , Aug. 22, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing both first-in-cla...
Ascentage Pharma Received US$100 Million Option Payment from Takeda
ROCKVILLE, Md. and SUZHOU, China, July 3, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing both first-in-class...